ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0751

Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Abstract Number: 0752

Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Abstract Number: 0753

Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 0754

Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients
Abstract Number: 0755

Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis
Abstract Number: 0756

Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients
Abstract Number: 0757

The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.
Abstract Number: 0758

Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Abstract Number: 0759

Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study
Abstract Number: 0760

The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 0761

Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Abstract Number: 0762

Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Abstract Number: 0763

Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
Abstract Number: 0764

Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
Abstract Number: 0765

Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].